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ISUMMARY AND CONCLUSIONS
The aim of this thesis was to assess the role of ibopamine, in the treatment of
patients with heart failure. Ibopamine is an orally active dopamine agonist which has
beneficial hemodynamic and neurohumoral effects. In the 10 Appendices both clinical
and experimental studies are reported that were designed to examine the efficacy and
safety of ibopamine. The clinical studies, which constitute Appendices 1-7, were
conducted in patients with mild, moderate and.severe heart failure. In these studies, we
evaluated the influence of ibopamine on hemodynamics (Appendices 3,4,6), renal
function (Appendices 5,6), neurohumoral parameters (Appendices 1,2,3), arrhythmias and
electrophysiology (Appendices 1,3), exercise tolerance (Appendices 1,2), signs and
symptoms of heart failure and side-effects (Appendices 1,5,7).
The experimental studies, which constitute Appendices 8-L0, were performed in
rats who underwent coronary ligation, thereby creating a model of myocardial infarction
and heart failure. We first studied the effects of ibopamine when administered late (6
weeks) after myocardial infarction (Appendix 8). Subsequent studies were undertaken
to investigate the effect of the drug when given early after myocardial infarction.
Accordingly, we evaluated the effects of ibopamine on ventricular remodeling (Appendix
9) and B-adrenoceptor density (Appendix 10).
The studies can be summarized as follows:
In Appendix 1, The Dutch Ibopamine Multicenter Trial (DIMT) is reported. T'his
double-blind, placebo-controlled trial was performed in 161 patients with mild to
moderate heart failure (80o/o f patients in NYHA class II and20oh in class III), who had
background treatment of low dose diuretics or no medication. Patients were randomized
to treatment with ibopamine (n=53), digoxin (n=55) or placebo (n=53) and follow-up
was 6 months. Of the 161 patients, 128 (80Vo) completed the study. Compared to
placebo, digoxin prevented a decrease in exercise time after 6 months (p=0.008 on
intention-to-treat analysis), but ibopamine did not. In a subgroup of patients with a
relatively preserved left ventricular function, ibopamine significantly increased exercise
time. However, in patients with more advanced disease, more patients dropped out of
the study for progression of heart failure on ibopamine than on digoxin, but the design
of the study (patients were allowed to have 0-80 mg furosemide at entry to the study, but
if more than 80 mg was required, they were considered a treatment failure), did not
allow definite conclusions to be drawn from this finding. On the neurohumoral level,
ibopamine and digoxin favorably affected plasma norepinephrine and plasma renin, but
did not influence plasma aldosterone concentrations. With regard to safety, no
proarrhythmia rvas observed with ibopamine and total mortality was similar between the




In Appendices 2 and 3, the effects of ibopamine in patients with moderate to
severe heart failure are reported. In these 2 studies, ibopamine was given as adjunct to
maximal, conventional treatment, including ACE-inhibitors. In Appendix2, the effect of
ibopamine on peak oxygen consumption (peak VO2) and plasma catecholamines (at rest
and during exercise) was studied in 11 patients with moderately severe heart failure.
After 6 weeks, peak VO2 was not significantly increased, but plasma norepinephrine was
significantly reduced, both at rest (-23Vo) and during exercise (aVo). This blunting of
sympathetic drive confirmed results from previous studies. As it has been suggested that
neurohumoral inhibition implies a beneficial long-term effect, it might therefore also be
true for ibopamine.
In Appendix 3, the electrophysiological profile of ibopamine was analyzed, both
invasively (programmed electrical stimulation) and noninvasively (Holter monitoring) in
12 patients with heart failure and documented ventricular tachycardia, who were also
treated with amiodarone. Invasive electrophysiologic measurements were performed at
baseline and after 1 tablet of 100 mg ibopamine. Ambulatory arrhythmias on 24 hour
Holter recordings were compared before and after 1 weeks ibopamine (3x 100 mg)
treatment. Electrophysiologic effects of ibopamine were related to changes in
hemodynamics and plasma catecholamines. Ibopamine did not significantly affect the
induction of ventricular tachyarrhythmias and the effective refractory period during
programmed electrical stimulation. Ambulatory arrhythmias on 24 hour Holter
monitoring were also unchanged. It is suggested that the favorable effect of ibopamine
on hemodynamics and plasma norepinephrine concentrations counteracts possible
adverse electrophysiologic effects of the drug, or that ibopamine lacks such
electrophysiologic effects.
Effects on invasive hemodynamics are often the first parameters studied, when a
new drug like ibopamine is introduced. This was indeed the first work which we
conducted in patients with heart failure (Appendix  ). The hemodynamic effects of
ibopamine were studied again later in relation to the electrophysiologic (Appendix 3) and
renal effects (Appendix 6). The effects of one tablet of 100 mg ibopamine were
investigated both in the presence and in the absence of concomitant medication
(including ACE-inhibitors) in 27 patients with moderate to severe heart failure. A
significant increase in cardiac index was observed, which was mainly attributed to a fall
in vascular resistance. Heart rate was not affected, and blood pressure slightly increased
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unchanged thereafter. In some patients a slight and transient, clinically asymptomatic,
increase in filling pressures was observed, which was followed by a longer lasting
decrease. It is concluded that ibopamine has an overall beneficial hemodynamic profile.
Its main effects are caused by peripheral vasodilation, of which the influence on the
arterial blood flow appears to be more pronounced than the effects on venous capacity.
In Appendix 5, the cardiac and renal effects of the most commonly used
dopaminergic agents (intravenous: dopamine and dopexamine, oral: levodopa,
fenoldopam and ibopamine) were compared, and data of studies in normal men, and in
patients with heart failure were reviewed. Intravenous dopamine is a valuable compound
in the intensive care setting. With regard to dopexamine, questions remain concerning
its additive value. Irvodopa has a beneficial hemodynamic profile and induces no
tolerance. Because of the high incidence of side-effects that are observed in the doses
required for patients with heart failure, the drug can however, not be recommended for
clinical use. Fenoldopam is a potent vasodilator, but it increases neurohumoral activity,
which limits its long-term efficacy. As a result, it is not being used anymore for heart
failure. Perhaps the drug may earn a place in the treatment of acute hypertensive crises.
Ibopamine appears to have the most favorable profile of the dopaminergic agents, at
least with respect to the long-term treatment of patients with heart failure.
The effects of ibopamine on renal parameters in relation to its cardiovascular
profile are reported in Appendix 6. Ten patients with mild to moderate heart failure,
who were clinically stable on digoxin and low-dose diuretics, underwent renal function
studies before and after 1 tablet of 100 mg ibopamine, while invasive hemodynamics
were monitored simultaneously. Ibopamine caused a 10Vo increase in effective renal
plasma flow and a 1,0Vo increase in glomerular filtration rate (both p< 0.05), while
filtration fraction and sodium excretion were unaffected. Cardiac output showed a similar
increase, without an effect on heart rate and blood pressure. The data therefore suggest,
that although ibopamine elicits favorable effects on renal function, this influence appears
to be secondary to systemic hemodynamic changes, but not because of a selective renal
effect.
In Appendix 7 the clinical data on ibopamine were reviewed, particularly the long-
term efficacy and safety. In most of the long-term trials that are discussed, large groups
of patients were studied, who were using open label (=not placebo-controlled)
ibopamine. One study that was performed earlier in our institution, is discussed, in which
25 patients with severe heart failure (NYHA class IV) were treated long-term with
ibopamine 100 mg tid. The one-year mortality that was found in this study (387a) is in
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Summary and Conclusions
agreement with data from other groups. Not included in this review are subsequent
studies of which the results were not yet available at that time, particularly the DIMT
study (Appendix 1). A1so, our animal experiments had not yet been concluded at that
time. Finally, some indications for the use of ibopamine in patients with heart failure are
provided.
The experimental work with ibopamine (Appendices 8-10), conducted at the
Department of Pharmacology and Clinical Pharmacology, was initiated to evaluate the
effects of ibopamine in a rat model of myocardial infarction and heart failure. This
model is currently the most widely used experimental heart failure model. Our aim was
to study the neurohumoral and hemodynamic effects of ibopamine when given in the
early and late phase after myocardial infarction. At the time we started these studies
(1990), it had become clear, that early intervention after myocardial infarction with ACE-
inhibitors was beneficial. Since the rat myocardium is endowed with predominantly a-
adrenoceptors (in contrast to man), there was initially some concern, however, whether
or not this model might be suitable to evaluate the effects of ibopamine.
We started therefore by giving ibopamine in the chronic phase (6 weeks) after
myocardial infarction (Appendix 8). The principal findings of this study were, that after
3 weeks treatment, ibopamine significantly reduced the elevated plasma norepinephrine
levels and cardiac (tissue) ACE-activity in rats with myocardial infarction. In contrast,
other plasma neurohumoral parameters and hemodynamics were not different between
infarcted and normal rats, and were also not affected by ibopamine. These findings
suggested, that ibopamine acted as a selective sympathetic antagonist in rats with heart
failure after myocardial infarction.
High levels of circulating catecholamines have been associated with:
1): ventricular hypertrophy and remodeling after myocardial infarction, because of
growth-stimulating effects on the cardiac myocyte, and
2): down-regulation of myocardial B-adrenoceptor density, with loss of contracti le
force and hemodynamic impairment.
Since ibopamine was shown to lower plasma norepinephrine levels in the first (pilot-)
study (and also to reduce cardiac ACE), we hypothesized, Ihat ibopamine a) might have
a beneficial effect on ventricular remodeling and b) as a result, myocardial B-adreno-
ceptor density might increase.
In Appendix 9, the effects of ibopamine on ventricular remodeling was studied,
and compared to the effects of captopril. Drug treatment was started within 24 hours
after myocardial infarction and the measurements were made 8 weeks later. Since
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receptor activation is related to the dose of ibopamine, both a high and a low dose was
used. These regimens were compared with a standard dose of captopril and with a
control (=no drug treatment) group. Ibopamine, particularly the higher dose, was found
to significantly reduce infarct size and ventricular dilatation, compared to untreated
infarcted rats. In the chronic phase, both ibopamine and captopril treated rats had a
higher blood pressure than untreated infarcted rats. In addition, a significant reduction
of the elevated plasma norepinephrine levels was caused by both ibopamine and
captopril, compared to untreated infarcted rats. It should be noted, that although
infarcted rats were again found to have significantly higher plasma norepinephrine levels
than controls, and also that ibopamine treatment significantly reduced these levels, the
values found in Appendix 9 (and 10) were markedly higher than in Appendix 8. This
difference may be explained by a different method of blood sampling. The conclusion
of Appendix 9 is, that both ibopamine and captopril favorably affect ventricular
remodeling after myocardial infarction. Since previous studies have indicated that
ibopamine has no vasodilating effects in the rat, it seems that the reduction in plasma
norepinephrine Ievels may play an important role in this beneficial effect. Moreover,
these findings confirmed the first part of our (aforementioned) hypothesis.
In Appendix 10, the influence of ibopamine on B-adrenoceptor density and
distribution (8,:Br) was investigated and this was related to possible changes in contracti-
le function. In this study we compared 3 treatment regimens: ibopamine, ibopamine plus
captopril, and no treatment (=control group). At the end of the study (after 8 weeks
treatment), untreated infarcted rats had a significant impairment of baseline
hemodynamics, compared to untreated normal rats. However, B-adrenoceptor density
(8n,"*) was unaffected, as well as the distribution of B, vs B, adrenoceptors. In rats with
myocardial infarction though, a significant increase in Bn,u" was observed with ibopamine
plus captopril compared to untreated animals (p=0.03), while ibopamine alone did not
induce a significant increase. It was concluded, that in this model of myocardial infarction
and heart failure, there is a dissociation between B-adrenoceptor density and left
ventricular function. Further, it was found that although there was no decrease in B.u*
(=down-regulation) in untreated infarcted rats, an increase inB-adrenoceptorswas found
in infarcted rats treated with ibopamine plus captopril. Although these findings do not
fully confirm the second part of our hypothesis, a treatment effect of ibopamine appears












The following conclusions can be drawn from these studies:
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The hemodynamic effect of ibopamine, an increase in cardiac output, is mainly
caused by peripheral vasodilation, although a mild positive inotropic effect could
possibly be present. Heart rate and blood pressure are not affected.
The renal effects of ibopamine are a (mild) increase in renal blood flow and
glomerular filtration rate, and are mainly secondary to the systemic hemodynamic
effect of the drug. The degree in which ibopamine exerts this renal effect depends
on the clinical situation in which these parameters are studied. This holds also
true for its stimulating effect on sodium excretion.
Ibopamine inhibits neurohumoral activation in patients with heart failure. Plasma
norepinephrine levels are reduced, both at rest and during exercise. Although the
drug does not directly affect the renin-angiotensin system, plasma aldosterone,
plasma renin and in experimental studies also cardiac (tissue) ACE may be
lowered under special circumstances, depending on the degree of neurohumoral
activation.
The electrophysiologic effects of ibopamine are mild and neither invasive nor
noninvasive studies indicate clinically significant proarrhythmic effects.
Small, but significant increases in exercise tolerance have been reported when
given alone or in combination with low-dose diuretics in mild heart failure. When
ibopamine is given as adjunct to maximal medication in more advanced disease,
this effect appears to be also present.
The effects of ibopamine on signs and symptoms of heart failure were also
beneficial when the drug was administered to the same patients groups.
Ibopamine is well tolerated and in general a low incidence of side-effects is





THE PLACE OF IBOPAMINE IN HEART FAILURE
The results of these studies are supported by other studies, which have been
summarized in Chapter 3. During the time when these studies were performed, the
treatment of heart failure has changed fundamentally due to new insights in its
pathophysiology, as well as results of recently published major trials with old and new
drugs. This is discussed in Chapter 2. When this is all put together, conclusions can be
drawn with regard to the role of ibopamine in the treatment of heart failure. This is
done in Chapter 4.
At the present time, the use of ibopamine can already be prescribed to all patients
who have chronic manifest heart failure, despite treatment with ACE-inhibitors and
diuretics, or as an alternative for ACE-inhibitors in patients who are intolerant for these
agents, with the primary aim to improve symptomatology and quality of life. In patients
with mild heart failure, ibopamine may be considered as monotherapy or in combination
with diuretics. Furthermore, because of its neurohumoral modulating properties and the
absence of proarrhythmia, one may even postulate a beneficial effect on the chain of
events that will lead to manifest heart failure. This means, early pharmacologic
intervention at a stage when only left ventricular dysfunction is present, without
symptoms of heart failure. Results of impending studies on survival and on remodeling
following myocardial infarction have to be awaited before definite conclusions can be
drawn on this issue. Nevertheless, ibopamine offers a new approach to the treatment of
patients with heart failure with promising perspectives.
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